Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Myos Corp. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific matter is being handled by Jennifer Lynn Cain within 1 distinct art unit. Because there is only 1 pending office action, the company's current prosecution profile lacks the diversity seen in larger portfolios. This concentration means that the company's immediate success in the Biotechnology & Pharmaceuticals sector is tied to a single point of review. The lack of multiple pending matters prevents the company from comparing examiner behaviors across different applications at this time.
The busiest examiner for the company manages the 1 pending office action. The focus on 1 distinct art unit and a single examiner means the company's immediate patent strategy is highly sensitive to the individual preferences of this specific official. With only 1 distinct examiner involved, there is no current data on broader examiner interactions for this portfolio. Practitioners must tailor their advocacy to the specific requirements of Jennifer Lynn Cain and the standards of the 1 distinct art unit involved to advance the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| CAIN, JENNIFER LYNN | 1 | 45.0% | +70.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19558906 | METHODS AND COMPOSITIONS FOR REDUCING MUSCLE LOSS AND/OR INHIBITING SARCOPENIA ASSOCIATED WITH WEIGHT LOSS | BOECKELMAN, JACOB A | — |
| 19413266 | Methods and Compositions for Managing and/or Alleviating Symptoms of Muscular Dystrophies and Other Genetic Muscular Disorders | CAIN, JENNIFER LYNN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19558906 | METHODS AND COMPOSITIONS FOR REDUCING MUSCLE LOSS AND/OR INHIBITING SARCOPENIA ASSOCIATED WITH WEIGHT LOSS | BOECKELMAN, JACOB A | 1655 | §103§112DP | Final Rejection | — | Pending | Mar 06, 2026 |
| 19413266 | Methods and Compositions for Managing and/or Alleviating Symptoms of Muscular Dystrophies and Other Genetic Muscular Disorders | CAIN, JENNIFER LYNN | 1655 | §102§103§112DP | Final Rejection | — | Pending | Dec 09, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial